Clinical-stage biotechnology company developing oral therapies that modulate the gut microbiome to treat inflammatory diseases.
Evelo Biosciences is a clinical-stage biotechnology company focused on developing oral therapies that work through the gut-body network. The company's approach involves using specific bacterial strains to modulate immune and metabolic pathways for treating inflammatory, metabolic, and oncologic diseases. Evelo's lead programs target conditions including inflammatory bowel disease, atopic dermatitis, and cancer, leveraging the connection between gut microbiome and systemic health.
Evelo Biosciences has received investment from 1 venture capital firm.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Mar 2026 | Series C+ | $85M | Lux Capital |
Clinical-stage biotechnology company developing oral therapies that modulate the gut microbiome to treat inflammatory diseases.
Evelo Biosciences has received investment from Flagship Pioneering. These venture capital firms and investors provide both capital and strategic support.
Evelo Biosciences has raised $260M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Evelo Biosciences was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Evelo Biosciences operates in the Biotech sector. Clinical-stage biotechnology company developing oral therapies that modulate the gut microbiome to treat inflammatory diseases.
